Lv3
220 积分 2022-04-12 加入
Into the Unknown: Regulatory Perspective on Identifying Optimized Dosages of Oncology Radiopharmaceutical Therapies
28天前
已完结
Eliminating Unnecessary Animal Testing
3个月前
已完结
Toward Greater Transparency at the FDA—Now Is the Time to Act
5个月前
已关闭
Oncology Drug Development: Challenges of Increasingly Available Therapies
5个月前
已关闭
Review Times For New Drugs And Submission Delays Among The FDA And 4 International Regulators, 2014–22
6个月前
已关闭
Review Times For New Drugs And Submission Delays Among The FDA And 4 International Regulators, 2014–22
6个月前
已关闭
The U.S. Food and Drug Administration’s Perspective on Chimeric Antigen Receptor T-Cell Therapies for Autoimmune and Rheumatic Conditions
6个月前
已完结
Discussion of Perspectives on Various Innovative Statistical Methodologies for Alzheimer’s Disease Clinical Trials
7个月前
已完结
Advancing CAR T-Cell Therapy
8个月前
已完结
Mitigating Limited Data Challenges to Improve Artificial Intelligence Integration in Rare Disease Drug Development
8个月前
已完结
皖公网安备34019202002308
